The number of patients with inflammatory bowel disease IBD, of non-Caucasian descent in Western Europe, is increasing. We aimed to explore the impact of ethnicity and country of birth on IBD phenotype. IBD patients treated in the eight University Medical Centers in The Netherlands Dutch IBD Biobank were divided into two groups according to their ethnicity: 1 Caucasian patients of Western and Central European descent CEU; and 2 patients of non-Caucasian descent non-CEU. The non-CEU group was subdivided according to country of birth, into: born in The Netherlands or Western Europe non-CEU European born; or born outside Western-Europe who migrated to The Netherlands non-CEU non-European born. Both comparisons were analysed for phenotype differences by chi-square test. The Dutch IBD Biobank included 2921 CEU patients and 233 non-CEU patients. Non-CEU Crohn's disease CD patients more often had upper gastro-intestinal disease 16% vs 8%, p = 0.001 and anal stenosis 10% vs 4%, p = 0.002 than CEU CD patients. The use of anti-tumour necrosis factor TNF agents and immunomodulators was higher in non-CEU IBD patients than in CEU IBD patients 45% vs 38%, p = 0.042 and 77% vs 66%, p = 0.001, respectively. Non-CEU IBD patients born in Europe n = 116 were diagnosed at a lower age than non-CEU IBD patients born outside Europe n = 115 at 22.7 vs 28.9 years old, p < 0.001. Non-Caucasians had more severe disease behaviour than Caucasians. Non-CEU patients born in Europe were diagnosed at a lower age with IBD than those born outside Europe who migrated to The Netherlands.